On Thursday, Dr. Marty Makary and Tracy Beth Hoeg wrote an article for The New York Post about the new Covid booster. Dr. Makary is a health care expert at Johns Hopkins University.

The article reports:

Pfizer’s version, approved this week as well, also has zero efficacy data and has not been tested on humans at all. We only have data about antibody production from 10 mice.

The FDA, or Moderna (frankly, it’s hard to tell the difference sometimes), should disclose what happened to the patient who took the new vaccine and had a complication that required medical attention.

The public has a right to know.

The last time the Biden administration approved and recommended a novel COVID bivalent booster, last fall, with no human-outcomes data, it was an epic fail.

Only 17% of Americans took it (and some of those were forced to do so by their employer or school).

Not foreseeing such weak public support for the booster last year, the Biden administration had prepaid pharma $4.9 billion for 171 million doses — many of which were tossed in the wastebasket.

Now it is making the same mistake.

Two weeks ago, the Biden administration upped its orders for the pediatric version of the new COVID vaccines from 14.5 million doses at $1.3 billion to 20 million doses for $1.7 billion, which is more than four times as many pediatric doses as were used last year.

There clearly seems to be a special push this time to give it to children — the same group European regulators are not supporting.

In fact, the original Moderna vaccine was banned in parts of Europe for people under age 30.

European doctors are not alone.

Dr. Paul Offit, a vaccine-mandate supporter and FDA adviser from the University of Pennsylvania, told The Atlantic this week that he’s not going to take the new COVID vaccine.

He didn’t take the bivalent booster last fall either, despite being 72 years old.

While he disagreed with Jha on the booster, he recently confessed, “Yes, he was wrong, but you know you can’t say that exactly.”

Yes, you can.

The article also notes:

Unlike influenza, COVID-19 is constantly circulating, so there is ample opportunity to run a trial; indeed, Moderna already ran a randomized trial.

Its trial of just 50 people began four months ago and oddly only reported 14-day side effects.

Why didn’t it enroll more people in its trial? Why didn’t it report three-month effectiveness and do a proper trial?

Conducting a placebo-controlled trial in people during this time would not only yield useful information; it would enable further study of those subjects three and six months from now, when a winter surge may occur.

Let’s be honest: Follow-up studies of COVID vaccines in general have revealed a disappointing truth — mild efficacy against infection is transient, lasting just a few months.

Perhaps Pfizer and Moderna knew the FDA regulatory process was greased for them and they didn’t have to.

Please follow the link to read the entire article. Our government is not doing us any favors by encouraging Covid booster shots.